Journal
IMMUNOTHERAPY
Volume 3, Issue 3, Pages 371-380Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.4
Keywords
antigen-based selection; B lymphocyte; biotin-avidin interaction; electrical pulse; hybridoma cell; immunoglobulin receptor; monoclonal antibody; myeloma cell; selective fusion
Categories
Funding
- Ministry of Education, Science, Sports and Culture of Japan
- Ministry of Economy, Trade and Industry
- Japan Science and Technology Agency
- Research Foundation for Electrotechnology of Chubu
- Iketani Science and Technology foundation
- Iwtani Naoji Foundation
Ask authors/readers for more resources
Hybridoma technology features effective usage of innate functions of both immune cells and cancers, allowing production of hybridoma cells, which continuously generate monoclonal antibodies specific to antigens of interest. For standard generation of hybridoma cells, B lymphocytes must be somatically fused with myeloma cells using various technologies. However, the methods generally do not necessarily result in selective fusion of target B lymphocytes with myeloma cells. To overcome this problem, we have developed a new hybridoma technology that involves preselection of B lymphocytes with target antigens based on immunoglobulin receptors and selective fusion of B cell myeloma cell complexes with electrical pulses. The advanced methodology, termed B-cell targeting, multitargeting and stereospecific targeting, may be applicable to simultaneous production of monoclonal antibodies, selective production of stereospecific monoclonal antibodies, and also to efficient generation of human monoclonal antibodies for clinical purposes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available